Provided by Tiger Trade Technology Pte. Ltd.

Bioxcel Therapeutics Inc.

1.17
-0.0900-7.14%
Volume:651.77K
Turnover:786.73K
Market Cap:28.66M
PE:-0.13
High:1.28
Open:1.28
Low:1.17
Close:1.26
52wk High:8.08
52wk Low:1.17
Shares:24.50M
Float Shares:22.09M
Volume Ratio:1.48
T/O Rate:2.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.0893
EPS(LYR):-23.5105
ROE:-1766.94%
ROA:-75.47%
PB:-0.30
PE(LYR):-0.05

Loading ...

Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI)

TIPRANKS
·
Yesterday

BioXcel Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 28

AI-driven biopharma firm BioXcel Therapeutics posts lower-than-expected Q4 loss on reduced SG&A costs

Reuters
·
Mar 27

BioXcel Therapeutics FY2025 net revenue drops 72% to $642,000; net loss widens to $69.9 million

Reuters
·
Mar 27

BRIEF-BioXcel Therapeutics Q4 Basic EPS USD -0.58 Vs. IBES Estimate USD -0.75

Reuters
·
Mar 27

BioXcel Therapeutics Q4 Revenue USD 256 Thousand VS. Ibes Estimate USD 162 Thousand

THOMSON REUTERS
·
Mar 27

BioXcel Therapeutics Q4 Operating Expenses USD 10.538 Million

THOMSON REUTERS
·
Mar 27

BioXcel Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview

Reuters
·
Mar 23

BioXcel Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Mar 17

BioXcel Therapeutics Closes $8.0 Million Direct Offering

MT Newswires Live
·
Mar 12

Press Release: BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Dow Jones
·
Mar 12

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

THOMSON REUTERS
·
Mar 11

Why Are BioXcel Therapeutics Shares Down Friday?

Benzinga_recent_news
·
Mar 06

BUZZ-U.S. STOCKS ON THE MOVE -Burlington Stores, Berkshire Hathaway, Bioventus

Reuters
·
Mar 05

BioXcel price target lowered to $6 from $10 at H.C. Wainwright

TIPRANKS
·
Mar 05

BUZZ-BioXcel jumps after mid-stage trial shows drug eases opioid withdrawal symptoms

Reuters
·
Mar 05

BioXcel Therapeutics Shares Rise 21.1% Premarket as Experimental Opioid‑Withdrawal Drug Shows Benefit in Mid-Stage Trial

THOMSON REUTERS
·
Mar 05

BRIEF-Bioxcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study Of BXCL501 For Treatment Of Opioid Withdrawal

Reuters
·
Mar 05

BioXcel Therapeutics Inc: Bxcl501 Demonstrated Clinical Benefits and Favorable Tolerability Profile for Treatment of Opioid Withdrawal Symptoms

THOMSON REUTERS
·
Mar 05

BioXcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study of Bxcl501 for Treatment of Opioid Withdrawal

THOMSON REUTERS
·
Mar 05